<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Calcium channel blockers for people with chronic kidney disease requiring dialysis - Mugendi, GA - 2020 | Cochrane Library</title> <meta content="Calcium channel blockers for people with chronic kidney disease requiring dialysis - Mugendi, GA - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011064.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Calcium channel blockers for people with chronic kidney disease requiring dialysis - Mugendi, GA - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011064.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011064.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Calcium channel blockers for people with chronic kidney disease requiring dialysis" name="citation_title"/> <meta content="George A Mugendi" name="citation_author"/> <meta content="University of Nairobi" name="citation_author_institution"/> <meta content="gendike@gmail.com" name="citation_author_email"/> <meta content="Florence M Mutua" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Tonya M Esterhuizen" name="citation_author"/> <meta content="Stellenbosch University" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011064.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011064.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011064.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011064.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antihypertensive Agents [*therapeutic use]; Bias; Blood Pressure [drug effects]; Calcium Channel Blockers [adverse effects, *therapeutic use]; Dihydropyridines [adverse effects, *therapeutic use]; Hypertension [*drug therapy]; Hypotension [chemically induced]; Randomized Controlled Trials as Topic; *Renal Dialysis; Renal Insufficiency, Chronic [complications, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011064.pub2&amp;doi=10.1002/14651858.CD011064.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011064\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011064\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pt","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011064.pub2",title:"Calcium channel blockers for people with chronic kidney disease requiring dialysis",firstPublishedDate:"Oct 1, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011064.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011064.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011064.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011064.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011064.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011064.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011064.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011064.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011064.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011064.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4343 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011064.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0071"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/appendices#CD011064-sec-0076"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/table_n/CD011064StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/table_n/CD011064StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Calcium channel blockers for people with chronic kidney disease requiring dialysis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#CD011064-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>George A Mugendi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#CD011064-cr-0005">Florence M Mutua</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#CD011064-cr-0006">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#CD011064-cr-0007">Tonya M Esterhuizen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information#CD011064-cr-0008">Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information/en#CD011064-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011064.pub2">https://doi.org/10.1002/14651858.CD011064.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011064-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011064-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011064-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011064-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011064-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011064-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011064-abs-0001" lang="en"> <section id="CD011064-sec-0001"> <h3 class="title" id="CD011064-sec-0001">Background</h3> <p>Calcium channel blockers (CCBs) are used to manage hypertension which is highly prevalent among people with chronic kidney disease (CKD). The treatment for hypertension is particularly challenging in people undergoing dialysis. </p> </section> <section id="CD011064-sec-0002"> <h3 class="title" id="CD011064-sec-0002">Objectives</h3> <p>To assess the benefits and harms of calcium channel blockers in patients with chronic kidney disease requiring dialysis. </p> </section> <section id="CD011064-sec-0003"> <h3 class="title" id="CD011064-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies to 27 April 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Specialised Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD011064-sec-0004"> <h3 class="title" id="CD011064-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) and quasi‐RCTs that compared any type of CCB with other CCB, different doses of the same CCB, other antihypertensives, control or placebo were included. The minimum study duration was 12 weeks. </p> </section> <section id="CD011064-sec-0005"> <h3 class="title" id="CD011064-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study quality and extracted data. Statistical analyses were performed using a random‐effects model and results expressed as risk ratio (RR), risk difference (RD) or mean difference (MD) with 95% confidence intervals (CI). </p> </section> <section id="CD011064-sec-0006"> <h3 class="title" id="CD011064-sec-0006">Main results</h3> <p>This review included 13 studies (24 reports) randomising 1459 participants treated with long‐term haemodialysis. Nine studies were included in the meta‐analysis (622 participants). No studies were performed in children or in those undergoing peritoneal dialysis. Overall, risk of bias was assessed as unclear to high across most domains. </p> <p>Random sequence generation and allocation concealment were at low risk of bias in eight and one studies, respectively. Two studies reported low risk methods for blinding of participants and investigators, and outcome assessment was blinded in 10 studies. Three studies were at low risk of attrition bias, eight studies were at low risk of selective reporting bias, and five studies were at low risk of other potential sources of bias. Overall, the certainty of the evidence was low to very low for all outcomes. No events were reported for cardiovascular death in any of the comparisons. Other side effects were rarely reported and studies were not designed to measure costs. </p> <p>Five studies (451 randomised adults) compared dihydropyridine CCBs to placebo or no treatment. Dihydropyridine CCBs may decrease predialysis systolic (1 study, 39 participants: MD ‐27.00 mmHg, 95% CI ‐43.33 to ‐10.67; <i>low certainty evidence</i>) and diastolic blood pressure level (2 studies, 76 participants; MD ‐13.56 mmHg, 95% CI ‐19.65 to ‐7.48; I<sup>2</sup> = 0%, <i>low certainty evidence</i>) compared to placebo or no treatment. Dihydropyridine CCBs may make little or no difference to occurrence of intradialytic hypotension (2 studies, 287 participants; RR 0.54, 95% CI 0.25 to 1.15; I<sup>2</sup> = 0%, <i>low certainty evidence</i>) compared to placebo or no treatment. Other side effects were not reported. </p> <p>Eight studies (1037 randomised adults) compared dihydropyridine CCBs to other antihypertensives. Dihydropyridine CCBs may make little or no difference to predialysis systolic (4 studies, 180 participants: MD 2.44 mmHg, 95% CI ‐3.74 to 8.62; I<sup>2</sup> = 0%, <i>low certainty evidence)</i> and diastolic blood pressure (4 studies, 180 participants: MD 1.49 mmHg, 95% CI ‐2.23 to 5.21; I<sup>2</sup> = 0%, <i>low certainty evidence)</i> compared to other antihypertensives. There was no evidence of a difference in the occurrence of intradialytic hypotension (1 study, 92 participants: RR 2.88, 95% CI 0.12 to 68.79; <i>very low certainty evidence</i>) between dihydropyridine CCBs to other antihypertensives. Other side effects were not reported. </p> <p>Dihydropyridine CCB may make little or no difference to predialysis systolic (1 study, 40 participants: MD ‐4 mmHg, 95% CI ‐11.99 to 3.99; <i>low certainty evidence</i> ) and diastolic blood pressure (1 study, 40 participants: MD ‐3.00 mmHg, 95% CI ‐7.06 to 1.06; <i>low certainty evidence</i> ) compared to non‐dihydropyridine CCB. There was no evidence of a difference in other side effects (1 study, 40 participants: RR 0.13, 95% CI 0.01 to 2.36; <i>very low certainty evidence</i>) between dihydropyridine CCB and non‐dihydropyridine CCB. Intradialytic hypotension was not reported. </p> </section> <section id="CD011064-sec-0007"> <h3 class="title" id="CD011064-sec-0007">Authors' conclusions</h3> <p>The benefits of CCBs over other antihypertensives on predialysis blood pressure levels and intradialytic hypotension among people with CKD who required haemodialysis were uncertain. Effects of CCBs on other side effects and cardiovascular death also remain uncertain. Dihydropyridine CCBs may decrease predialysis systolic and diastolic blood pressure level compared to placebo or no treatment. No studies were identified in children or peritoneal dialysis. Available studies have not been designed to measure the effects on costs. The shortcomings of the studies were that they recruited very few participants, had few events, had very short follow‐up periods, some outcomes were not reported, and the reporting of outcomes such as changes in blood pressure was not done uniformly across studies. </p> <p>Well‐designed RCTs, conducted in both adults and children with CKD requiring both haemodialysis and peritoneal dialysis, evaluating both dihydropyridine and non‐dihydropyridine CCBs against other antihypertensives are required. Future research should be focused on outcomes relevant to patients (including death and cardiovascular disease), blood pressure changes, risk of side effects and healthcare costs to assist decision‐making in clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011064-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011064-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011064-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011064-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011064-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011064-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011064-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011064-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011064-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011064-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011064-abs-0002" lang="en"> <h3>Calcium channel blockers for people with chronic kidney disease requiring dialysis</h3> <p><b>What is the issue?</b> People with long‐term kidney disease or chronic kidney disease (CKD) often develop high blood pressure (hypertension), and those with advanced CKD need dialysis when their kidneys are no longer unable to function. Treatment for hypertension is often challenging for people with advanced CKD undergoing dialysis. Several medications are used to treat high blood pressure including calcium channel blockers (CCBs). </p> <p>We wanted to find out whether the use of CCBs in people with CKD undergoing haemodialysis or peritoneal dialysis had any added benefits over other medications used to treat hypertension or placebo (no active treatment) in lowering the blood pressure, risk of death and undesired effects. </p> <p><b>What did we do?</b> We searched the literature up to April 2020 to identify all studies that assessed the use of CCBs in adults and children with hypertension and CKD undergoing haemodialysis or peritoneal dialysis. Each study was assessed for possible bias on several pre‐determined domains. We pooled the results of studies that reported on the same outcomes for similar comparisons and reported the overall effects. We applied a system called "GRADE" to assess the quality of the evidence that we found. </p> <p><b>What did we find?</b> We included 13 studies randomising 1459 adults undergoing haemodialysis. We did not find any studies in children and there were no studies in patients undergoing peritoneal dialysis. Patients were randomised to CCBs, other medications used to treat hypertension, or placebo or standard care. Some studies were short‐term (over few months) and heart‐related complications were not assessed. The benefit of CCBs over other medications was unclear, possibly due to the small number of participants and the overall number of events. When compared to placebo or no treatment CCBs may decrease blood pressure before haemodialysis, although the quality of the evidence was low. </p> <p><b>Conclusions</b> The benefits of CCBs over other medications to treat hypertension could not be determined, while CCBs may lower blood pressure compared to placebo or usual care. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011064-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011064-sec-0071"></div> <h3 class="title" id="CD011064-sec-0072">Implications for practice</h3> <section id="CD011064-sec-0072"> <p>Dihydropyridine CCBs had uncertain effects on predialysis systolic and diastolic blood pressure, cardiovascular death, and occurrence of intradialytic hypotension compared to other antihypertensives. Data were provided by only a few studies with limited number of participants who experienced few events. </p> <p>Dihydropyridine CCBs may reduce predialysis systolic and diastolic blood pressure levels compared to placebo or no treatment, although there was low certainty evidence; further investigation with adequately powered RCTs are needed. </p> <p>Scant evidence were available to detect differences between dihydropyridine CCBs and non‐dihydropyridine CCBs and no data were available to compare different doses or the efficacy of different medications from the same drug class. Other side effects were rarely reported and no studies addressed costs. No data for treatment effects in children and in peritoneal dialysis were identified. </p> </section> <h3 class="title" id="CD011064-sec-0073">Implications for research</h3> <section id="CD011064-sec-0073"> <p>Future RCTs with adequate sample size and longer follow‐up are required to assess the benefits and harms of dihydropyridine and non‐dihydropyridine CCBs compared to other antihypertensives, placebo or control in patients with CKD requiring dialysis. Furthermore, research in children and in patients treated with peritoneal dialysis are needed. We recommend these adequately powered prospective RCTS be undertaken. Key outcomes relevant for patients (including death and cardiovascular disease), changes in blood pressure, health care costs and side effects should be reported to assist clinical decision‐making. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011064-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011064-sec-0008"></div> <div class="table" id="CD011064-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus placebo/control in people with chronic kidney disease requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydropyridine calcium channel blockers versus placebo/control in people with CKD requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD requiring dialysis<br/><b>Setting:</b> France, Germany, Japan, Russia </p> <p><b>Intervention:</b> dihydropyridine calcium channel blockers (amlodipine, cilnidipine or nitrendipine)<br/><b>Comparison:</b> placebo/control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dihydropyridine calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis systolic blood pressure</b><br/>follow‐up 3.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis systolic blood pressure level in the dihydropyridine calcium channel blockers group was 27.00 mmHg lower (43.33 to 10.67 mmHg lower) than the placebo group <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis diastolic blood pressure</b><br/>mean follow‐up 4.9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis diastolic blood pressure level in the placebo/control group ranged from 98 to 104.1 mmHg </p> <p>The mean predialysis diastolic blood pressure level in the placebo/control group was 13.56 mmHg lower (19.65 to 7.48 mmHg lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>mean follow‐up 3.4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradialytic hypotension</b> </p> <p>mean follow‐up 16.4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/>(31 to 141) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54 (0.25 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>3,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> Chronic kidney disease; <b>HD:</b> Haemodialysis; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Studies were not designed to measure effects of dihydropyridine calcium channel blockers on predialysis systolic blood pressure level in haemodialysis<br/><sup>2</sup> Evidence certainty was downgraded by one level due to study limitations. The study had unclear risks for allocation concealment and blinding (participants and/or investigators)<br/><sup>3</sup> Evidence certainty was downgraded by one level due to the small number of participants/events (optimal Information size criterion not met)<br/><sup>4</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risk for sequence generation, all studies had unclear risks for allocation concealment and some of them were not blinded (participants and/or investigators)<br/><sup>5</sup> Cardiovascular death was reported by as a single study with zero events in both groups; studies were not designed to measure effects of dihydropyridine calcium channel blockers or placebo/control on cardiovascular death in HD<br/><sup>6</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risks for allocation concealment and were not blinded (participants and/or investigators) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011064-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus other antihypertensives in people with chronic kidney disease requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydropyridine calcium channel blockers versus other antihypertensives in people with CKD requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD requiring dialysis<br/><b>Setting:</b> France, Turkey, Russia </p> <p><b>Intervention:</b> dihydropyridine calcium channel blockers (amlodipine or nifedipine)<br/><b>Comparison:</b> other antihypertensives (all studies reported ACEi including, enalapril, perindopril or ramipril) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other antihypertensives</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dihydropyridine calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis systolic blood pressure</b><br/>mean follow‐up 10.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis systolic blood pressure level in the other antihypertensive group ranged from 129 to 150 mmHg </p> <p>The mean predialysis systolic blood pressure level in the dihydropyridine calcium channel blockers group was 2.44 mmHg higher (3.74 lower to 8.62 mmHg higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis diastolic blood pressure</b><br/>mean follow‐up 10.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis diastolic blood pressure level in the other antihypertensive group ranged from 80 to 88.3 mmHg </p> <p>The mean predialysis diastolic blood pressure level in the dihydropyridine calcium channel blockers group was 1.49 mmHg higher (2.23 lower to 5.21 mmHg higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradialytic hypotension</b> </p> <p>follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1/47**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.88</p> <p>(0.12 to 68.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>5,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> Chronic kidney disease; <b>HD:</b> Haemodialysis; <b>ACEi:</b> Angiotensin‐converting enzyme inhibitors; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> <p>**Event rate derived from the raw data. A "per thousand" rate is non‐informative in view of the scarcity of evidence and zero events in the control group. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risk for sequence generation, all studies had unclear risks for allocation concealment and the majority of them were not blinded (participants and/or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to the small number of participants/events (optimal information size criterion not met) </p> <p><sup>3</sup> Cardiovascular death was reported by as a single study with zero events in both groups; studies were not designed to measure cardiovascular death<br/><sup>4</sup> Occurrence of intradialytic hypotension was reported by as a single study; studies were not designed to measure the occurrence of intradialytic hypotension in HD </p> <p><sup>5</sup> Evidence certainty was downgraded by one level due to study limitations. The study had unclear risks for allocation concealment and was not blinded (participants and/or investigators) </p> <p><sup>6</sup> Evidence certainty was downgraded by two levels due to imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011064-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with chronic kidney disease requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with CKD requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD requiring dialysis </p> <p><b>Setting:</b> Italy </p> <p><b>Intervention:</b> dihydropyridine calcium channel blockers (amlodipine) </p> <p><b>Comparison:</b> non‐dihydropyridine calcium channel blockers (verapamil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Non‐dihydropyridine calcium channel blockers</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dihydropyridine calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis systolic blood pressure</b> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis systolic blood pressure level in the dihydropyridine calcium channel blockers group was 4 mmHg lower (11.99 lower to 3.99 mmHg higher) than non‐dihydropyridine calcium channel blockers <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis diastolic blood pressure</b> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis diastolic blood pressure level in the dihydropyridine calcium channel blockers group was 3.00 mmHg lower (7.06 lower to 1.06 mmHg higher) than non‐dihydropyridine calcium channel blockers <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>1,3,4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradialytic hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other side effects</b><sup>1,5</sup> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3/19 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.13</b> </p> <p>(0.01 to 2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> Chronic kidney disease; <b>HD:</b> Haemodialysis; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> <p>**Event rate derived from the raw data. A "per thousand" rate is non‐informative in view of the scarcity of evidence and zero events in the dihydropyridine calcium channel blocker group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Studies not designed to measure this outcome<br/><sup>2</sup> Evidence certainty was downgraded by one level due to study limitations. The study had unclear risks for allocation concealment and was not blinded (participants and/or investigators)<br/><sup>3</sup> Evidence certainty was downgraded by one level due to the small number of participants/events (optimal information size criterion not met) </p> <p><sup>4</sup> Cardiovascular death was reported by as a single study with zero events in both groups<br/><sup>5</sup> Other side effects included headache reported in non‐dihydropyridine calcium channel blockers group, while no events were reported in dihydropyridine calcium channel blockers group </p> <p><sup>6</sup> Evidence certainty was downgraded by two levels due to imprecision </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011064-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011064-sec-0009"></div> <p>CKD is a growing health concern associated with a high risk of adverse outcomes. Its global prevalence is increasing at a rate of 8% per year (<a href="./references#CD011064-bbs2-0047" title="RuilopeLM . Angiotensin receptor blockers: RAAS blockade and renoprotection. Current Medical Research &amp; Opinion2008;24(5):1285-93. [18366863]">Ruilope 2008</a>). CKD aetiology differs by region, age, gender, and race. In Europe, Japan and the United States, diabetic nephropathy is the leading cause of CKD, while in the developing world, chronic glomerulonephritis and systemic hypertension are the leading causes (<a href="./references#CD011064-bbs2-0047" title="RuilopeLM . Angiotensin receptor blockers: RAAS blockade and renoprotection. Current Medical Research &amp; Opinion2008;24(5):1285-93. [18366863]">Ruilope 2008</a>). Hypertension as a complication is highly prevalent in patients who have end‐stage kidney disease (ESKD). In India, a population‐based study determined that the crude and age‐adjusted ESKD rates were 151 and 232 per million population, respectively. The number of patients requiring dialysis in India has been estimated at 55,000 with an annual growth rate of between 10% and 20% (<a href="./references#CD011064-bbs2-0041" title="JhaV . Current status of end-stage renal disease care in India and Pakistan. Kidney International - Supplement2013;3(2):S157-60. [DOI: 10.1038/kisup.2013.3]">Jha 2013</a>). </p> <p>From the 1990s, there has been an increase in CKD incidence of unknown aetiologies observed in several countries ‐ El Salvador, Nicaragua, Costa Rica, Sri Lanka, Egypt, and India. The disease seems to have a predominance in young male farm workers and the most common aetiology was chronic tubulointerstitial nephritis (<a href="./references#CD011064-bbs2-0032" title="AlmaguerM , HerreraR , OrantesCM . Chronic kidney disease of unknown etiology in agricultural communities. MEDICC Review2014;16(2):9-15. [MEDLINE: 24878644]">Almaguer 2014</a>; <a href="./references#CD011064-bbs2-0054" title="WanigasuriyaK . Update on uncertain etiology of chronic kidney disease in Sri Lanka's north central dry zone. MEDICC Review2014;16(2):61-5. [MEDLINE: 24878651]">Wanigasuriya 2014</a>). </p> <p>Studies in East Africa revealed a prevalence of hypertension ranging between 61.5% and 76% among patients with varying degrees of CKD (<a href="./references#CD011064-bbs2-0044" title="MaritimM . Prevalance of peripheral arterial disease among chronic kidney disease patients at Kenyatta National Hospital [MMed Thesis]. Nairobi (Kenya): University of Nairobi, 2007.">Maritim 2007</a>; <a href="./references#CD011064-bbs2-0046" title="RajulaA . Prevalence of hypertension and adequacy of its control in chronic kidney disease patients at the renal clinic at Kenyatta National Hospital [MMed Thesis]. Nairobi (Kenya): University of Nairobi, 2009.">Rajula 2009</a>) which illustrated the inadequacy of blood pressure control in this population. It is imperative therefore to ensure adequate blood pressure control in patients with ESKD requiring dialysis. This entails the use of appropriate antihypertensives to provide better health outcomes. </p> <section id="CD011064-sec-0010"> <h3 class="title" id="CD011064-sec-0010">Description of the condition</h3> <p>CKD is defined as the progressive loss of kidney function occurring over several months to years and is characterised by gradual kidney scarring (<a href="./references#CD011064-bbs2-0035" title="DipiroJ , TalbertRL , YeeGC , MatzkeGR , WellsBG , PoseyLM . Chronic kidney disease: progression - modifying therapies. In: Michael Weitz, Karen G Edmonson, editors(s). Pharmacotherapy a Pathophysiologic Approach. 8th edition. New York: McGraw Hill, 2011:767-86.">Dipiro 2011</a>). CKD is categorised by the level of kidney function into stages 1 to 5 as proposed by the widely‐accepted United States Kidney Disease Outcomes Quality Initiative (KDOQI); staging is determined by the glomerular filtration rate (GFR) (<a href="./references#CD011064-bbs2-0042" title="LeveyAS , CoreshJ , BalkM , KauszAT , LevinA , SteffesMW , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.[Erratum appears in Ann Intern Med. 2003 Oct 7;139(7):605]. Annals of Internal Medicine2003;139(2):137-47. [MEDLINE: 12859163]">Levey 2003</a>). </p> <p>The more recently published Kidney Disease Improving Guidelines Outcomes (KDIGO) 2012 clinical practice guidelines for the evaluation and management of CKD have a slightly different staging of CKD. They recommend that CKD be classified based on the cause, GFR category and albuminuria category (CGA). GFR categories are classified as G1, G2, G3a, G3b, G4 and G5 (<a href="./references#CD011064-bbs2-0036" title="EknoyanG , LameireN , EckardtK , KasiskeB , WheelerD , AbboudO , et al. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney International - Supplement2013;3(1):1-150. [DOI: 10.1038/kisup.2012.73]">Eknoyan 2013</a>). </p> <p>Data from the 1998 to 2004 National Health and Nutrition Examination Survey (NHANES) revealed a rise in CKD prevalence. Prevalence rose in people aged over 20 years from 14.5% in 1988 to 16.8% in 1994 (<a href="./references#CD011064-bbs2-0045" title="OnuigboMA . Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution. Nephron2009;113(2):c63-70. [MEDLINE: 19602900]">Onuigbo 2009</a>). The 2003 to 2006 survey reported an increase in stage 3 CKD prevalence from 5.7% in 1988 to 8.1% in 1994 (<a href="./references#CD011064-bbs2-0035" title="DipiroJ , TalbertRL , YeeGC , MatzkeGR , WellsBG , PoseyLM . Chronic kidney disease: progression - modifying therapies. In: Michael Weitz, Karen G Edmonson, editors(s). Pharmacotherapy a Pathophysiologic Approach. 8th edition. New York: McGraw Hill, 2011:767-86.">Dipiro 2011</a>). </p> </section> <section id="CD011064-sec-0011"> <h3 class="title" id="CD011064-sec-0011">Description of the intervention</h3> <p>CCBs are antihypertensive agents that act on both myocardial cells and blood vessels. CCBs are classified broadly as either dihydropyridine or non‐dihydropyridine types. Dihydropyridine CCBs include nifedipine, which is the prototype in this group; others include amlodipine, felodipine, isradipine, nicardipine, nimodipine, nitrendipine, nisoldipine, efonipidine and cilnidipine. The non‐dihydropyridine subclass includes diltiazem and verapamil which are the prototypes for the benzodiazepine and phenylalkylamine class of CCB. Gallopamil, a derivative of verapamil, is also classified as a non‐dihydropyridine CCB (<a href="./references#CD011064-bbs2-0038" title="HartP , BakrisGL . Calcium antagonists: do they equally protect against kidney injury?Kidney International2008;73(7):795-6. [MEDLINE: 18340349]">Hart 2008</a>). </p> </section> <section id="CD011064-sec-0012"> <h3 class="title" id="CD011064-sec-0012">How the intervention might work</h3> <p>CCBs are vasodilators, although vasodilatory ability is not equal across all classes; the dihydropyridine CCBs are more potent than non‐dihydropyridine CCBs (<a href="./references#CD011064-bbs2-0050" title="SicaDA . Calcium channel blocker class heterogeneity; select aspects of pharmacokinetics and pharmacodynamics. Journal of Clinical Hypertension2005;7(4 Suppl 1):21-6. [MEDLINE: 15858399]">Sica 2005</a>). </p> <p>Both CCBs classes inhibit two types of voltage dependent channels: a high voltage activated calcium channel including P/Q, L, N, and R type channels, and low voltage activated T type channel (<a href="./references#CD011064-bbs2-0038" title="HartP , BakrisGL . Calcium antagonists: do they equally protect against kidney injury?Kidney International2008;73(7):795-6. [MEDLINE: 18340349]">Hart 2008</a>). By preferentially binding to L type channels in the vasculature, dihydropyridine CCBs cause vasodilatation and subsequent drop in blood pressure. The non‐dihydropyridine CCBs bind preferentially to L type channels in the cardiac muscles, more so on the sino‐atrial and atrioventricular nodes, causing negative chronotropic effects and decreasing sympathetic nervous system activity. These effects cause blood pressure to decrease (<a href="./references#CD011064-bbs2-0033" title="BasileJ . The role of existing and newer calcium channel blockers in the treatment of hypertension. Journal of Clinical Hypertension2004;6(11):621-9. [MEDLINE: 15538095]">Basile 2004</a>). </p> </section> <section id="CD011064-sec-0013"> <h3 class="title" id="CD011064-sec-0013">Why it is important to do this review</h3> <p>Most people undergoing dialysis have hypertension that is difficult to control; this contributes to increased cardiovascular morbidity and mortality (<a href="./references#CD011064-bbs2-0040" title="InrigJK . Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in Dialysis2010;23(3):290-7. [MEDLINE: 20374548]">Inrig 2010</a>; <a href="./references#CD011064-bbs2-0053" title="Van BurenPN , TotoR , InrigJK . Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. Current Opinion in Nephrology &amp; Hypertension2012;21(1):15-23. [MEDLINE: 22123207]">Van Buren 2012</a>). The reported prevalence of hypertension among people on dialysis was 86% in an American cohort of 2535 clinically stable, adults on dialysis. Of these, only 30% had adequately controlled blood pressure (<a href="./references#CD011064-bbs2-0031" title="AgarwalR , NissensonAR , BatlleD , CoyneDW , TroutJR , WarnockDG . Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. American Journal of Medicine2003;115(4):291-7. [MEDLINE: 12967694]">Agarwal 2003</a>). Drugs used before development of ESKD may no longer provide viable options. Some drugs are dialyzable and use would result in a rise in blood pressure during dialysis (<a href="./references#CD011064-bbs2-0040" title="InrigJK . Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in Dialysis2010;23(3):290-7. [MEDLINE: 20374548]">Inrig 2010</a>; <a href="./references#CD011064-bbs2-0053" title="Van BurenPN , TotoR , InrigJK . Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. Current Opinion in Nephrology &amp; Hypertension2012;21(1):15-23. [MEDLINE: 22123207]">Van Buren 2012</a>). Clinicians are faced with the challenge of choosing an appropriate therapy for controlling blood pressure for people with ESKD undergoing dialysis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011064-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011064-sec-0014"></div> <p>To assess the benefits and harms of calcium channel blockers in patients with chronic kidney disease requiring dialysis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011064-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011064-sec-0015"></div> <section id="CD011064-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011064-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at the effects of CCB on blood pressure control in patients with CKD undergoing dialysis. The minimum study duration was 12 weeks. Cross‐over studies were excluded unless they had a washout period between treatments. </p> </section> <section id="CD011064-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD011064-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>All patients with CKD requiring dialysis (stage 5 as defined by the K/DOQI guidelines (<a href="./references#CD011064-bbs2-0042" title="LeveyAS , CoreshJ , BalkM , KauszAT , LevinA , SteffesMW , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.[Erratum appears in Ann Intern Med. 2003 Oct 7;139(7):605]. Annals of Internal Medicine2003;139(2):137-47. [MEDLINE: 12859163]">Levey 2003</a>) or stage G5 as defined by the KDIGO guidelines (<a href="./references#CD011064-bbs2-0036" title="EknoyanG , LameireN , EckardtK , KasiskeB , WheelerD , AbboudO , et al. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney International - Supplement2013;3(1):1-150. [DOI: 10.1038/kisup.2012.73]">Eknoyan 2013</a>). We included patients who underwent either haemodialysis or peritoneal dialysis. There were no restrictions on age, gender, or race. </p> <p>The participants were comorbid with hypertension as defined by the seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VII) (<a href="./references#CD011064-bbs2-0034" title="ChobanianAV , BakrisGL , BlackHR , CushmanWC , GreenLA , Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003;42(6):1206-52. [MEDLINE: 14656957]">Chobanian 2003</a>). Participants with or without diabetes (either type 1 or 2) were included. Patients with heart failure as classified by the New York Heart Association (NYHA) stages I to IV and angina were included. </p> </section> <section id="CD011064-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>Kidney transplant patients and patients with CKD stages 1 to 4 and stages G1 to G4 as per the K/DOQI guidelines (<a href="./references#CD011064-bbs2-0042" title="LeveyAS , CoreshJ , BalkM , KauszAT , LevinA , SteffesMW , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.[Erratum appears in Ann Intern Med. 2003 Oct 7;139(7):605]. Annals of Internal Medicine2003;139(2):137-47. [MEDLINE: 12859163]">Levey 2003</a>) and KDIGO guidelines (<a href="./references#CD011064-bbs2-0036" title="EknoyanG , LameireN , EckardtK , KasiskeB , WheelerD , AbboudO , et al. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney International - Supplement2013;3(1):1-150. [DOI: 10.1038/kisup.2012.73]">Eknoyan 2013</a>) respectively were excluded. Studies where follow‐up was less than 12 weeks were excluded. </p> </section> </section> <section id="CD011064-sec-0021"> <h4 class="title">Types of interventions</h4> <p>Any type of CCB compared with other CCB, different doses of the same CCB, other antihypertensives, or placebo/control/usual treatment were included. Intervention types were to be assessed as follows. </p> <p> <ol id="CD011064-list-0001"> <li> <p>CCB versus placebo/control/usual treatment</p> <ol id="CD011064-list-0002"> <li> <p>Dihydropyridine CCB versus placebo/control/usual treatment</p> </li> <li> <p>Non‐dihydropyridine CCB versus placebo/control/usual treatment</p> </li> </ol> </li> <li> <p>CCB versus CCB</p> <ol id="CD011064-list-0003"> <li> <p>Dihydropyridine CCB versus dihydropyridine CCB</p> </li> <li> <p>Dihydropyridine CCB versus non‐dihydropyridine CCB</p> </li> <li> <p>Non‐dihydropyridine CCB versus non‐dihydropyridine CCB</p> </li> </ol> </li> <li> <p>Different doses of CCB</p> <ol id="CD011064-list-0004"> <li> <p>Dihydropyridine CCB</p> </li> <li> <p>Non‐dihydropyridine CCB</p> </li> </ol> </li> <li> <p>CCB versus other antihypertensives</p> <ol id="CD011064-list-0005"> <li> <p>Dihydropyridine CCB versus other antihypertensives</p> </li> <li> <p>Non‐dihydropyridine CCB versus other antihypertensives</p> </li> </ol> </li> </ol> </p> <p>The review was amended as newer drugs that had been licensed become available. All drugs were administered orally. The dosages were those that were required for control of hypertension or appropriately adjusted dosages for reduced GFR and dialysis. </p> <p>Combination preparations with other antihypertensives other than CCB were not included.</p> </section> <section id="CD011064-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD011064-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011064-list-0006"> <li> <p>Cardiovascular death</p> </li> <li> <p>Predialysis blood pressure (systolic and diastolic)</p> </li> <li> <p>Intradialytic hypotension.</p> </li> </ol> </p> </section> <section id="CD011064-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011064-list-0007"> <li> <p>Incidence of other adverse events (e.g. reflex tachycardia, headache, constipation, bradycardia and heart block, myocardial infarction) related to the interventions </p> </li> <li> <p>Cost: total healthcare costs.</p> </li> </ol> </p> </section> </section> </section> <section id="CD011064-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011064-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> to 27 April 2020 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD011064-list-0008"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov</p> </li> </ol> </p> <p>Studies contained in the Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the "Specialised Register" section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD011064-sec-0077">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD011064-sec-0027"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD011064-list-0009"> <li> <p>Reference lists of review articles, relevant studies, and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD011064-sec-0028"> <h3 class="title" id="CD011064-sec-0028">Data collection and analysis</h3> <section id="CD011064-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may have been relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable, however studies and reviews that might have included relevant data or information on trials were retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text, of these studies to determine which studies satisfied the inclusion criteria. The two authors compared their lists and any differences were resolved by discussion and, where this failed, by arbitration by a third author. </p> </section> <section id="CD011064-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study exists, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data was used. Any discrepancy between published versions was highlighted. Differences in opinion on data collection was resolved by discussion and, where this failed, by arbitration by a third author. </p> </section> <section id="CD011064-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD011064-bbs2-0039" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) (see <a href="./appendices#CD011064-sec-0078">Appendix 2</a>). </p> <p> <ul id="CD011064-list-0010"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD011064-list-0011"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Were reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD011064-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. death, adverse events such as hypotension, cardiovascular death) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (blood pressure), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used. Studies that reported change from baseline scores were meta‐analysed with studies reporting final value scores using the mean difference. In this case, if standard deviation of change was not reported, this was imputed (<a href="./references#CD011064-bbs2-0039" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Studies that reported time to event of outcomes as hazard ratios and CIs were meta‐analysed with studies that reported risk ratios where the proportional hazards assumption was reasonable. Otherwise, these studies were analysed as dichotomous data. </p> </section> <section id="CD011064-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We did not foresee the use of non‐standard design studies such as cross‐over trials and cluster‐RCTs would be included in the review. However, multiple arm studies were found and included. In such cases, all intervention groups that were relevant to the review were included. </p> </section> <section id="CD011064-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing the corresponding author) and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat (ITT), as‐treated and per‐protocol (PP) population was carefully performed. Attrition rates, for example drop‐outs, losses to follow‐up and withdrawals were investigated. Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward (LOCF)) were critically appraised (<a href="./references#CD011064-bbs2-0039" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD011064-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (Higgins 2003). I² values of 25%, 50% and 75% correspond to low, medium, and high levels of heterogeneity. </p> </section> <section id="CD011064-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were to be used to assess for the potential existence of small study bias (<a href="./references#CD011064-bbs2-0039" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD011064-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD011064-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were used to explore possible sources of heterogeneity (e.g. participants, interventions, and study quality). Heterogeneity among participants could have been related to age, gender, ethnicity/race, renal pathology, type of dialysis and co morbidities (CVD, hypertension, diabetes mellitus). Heterogeneity in treatments could have been related to prior agents used and the agent, dose, and duration of therapy. Adverse effects were tabulated and assessed with descriptive techniques, as they were likely to be different for the various agents used. Where possible, the risk difference with 95% CI was calculated for each adverse effect, either compared with no treatment or another agent. </p> </section> <section id="CD011064-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of the following factors on effect size: </p> <p> <ul id="CD011064-list-0012"> <li> <p>repeating the analysis excluding unpublished studies;</p> </li> <li> <p>repeat the analysis excluding studies with high risk of bias;</p> </li> <li> <p>repeating the analysis excluding any very long or large studies to establish how much they dominate the results; </p> </li> <li> <p>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country. </p> </li> </ul> </p> </section> <section id="CD011064-sec-0040"> <h4 class="title">'Summary of findings' tables</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD011064-bbs2-0048" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD011064-bbs2-0037" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD011064-bbs2-0049" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD011064-list-0013"> <li> <p>Predialysis systolic blood pressure</p> </li> <li> <p>Predialysis diastolic blood pressure</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Intradialytic hypotension</p> </li> <li> <p>Other side effects.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011064-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011064-sec-0041"></div> <section id="CD011064-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD011064-sec-0043"> <h4 class="title">Results of the search</h4> <p>Our search identified 625 reports; 55 duplicate records were deleted. We screened 570 titles and abstracts and excluded 525 records which did not meet our inclusion criteria (not randomised, wrong population, or wrong intervention). We assessed 45 full text reports and excluded a further 20 reports (16 studies). One study (recently completed but not published) has been listed as awaiting classification (<a href="./references#CD011064-bbs2-0030" title="CiceG . Cardiovascular events in hypertensive hemodialysed patients: aliskiren versus amlodipine. a randomized, double-blind study. www.clinicaltrials.gov/ct2/show/NCT01394770 (first received 13 July 2011). ">NCT01394770</a>). We included 13 studies (24 reports) randomising 1459 participants; nine studies (15 reports; 622 participants) were included in our meta‐analyses. </p> <p>See <a href="#CD011064-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011064-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011064-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011064-sec-0044"> <h4 class="title">Included studies</h4> <p>Twelve studies evaluated dihydropyridine CCBs (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>), and one study (<a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>) compared dihydropyridine CCBs to non‐dihydropyridine CCBs. </p> <p><a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a> was a four‐arm study compared amlodipine either to an ACEi (perindopril), dual therapy or no intervention, while <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a> was a three arms study compared amlodipine either to an ACEi (enalapril) or an ARB (losartan). </p> <section id="CD011064-sec-0045"> <h5 class="title">Dihydropyridine CCB versus placebo or no treatment</h5> <p>Five studies compared dihydropyridine CCB to placebo or no treatment. <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a> (40 participants) and <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a> (40 participants) compared nitrendipine to placebo; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a> (251 participants) compared amlodipine to placebo; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a> (37 participants) compared amlodipine to no treatment; and <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a> (51 participants) compared cilnidipine to no treatment. </p> <p>The outcomes assessed were predialysis systolic (<a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>) and diastolic blood pressure (<a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>), cardiovascular death (<a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>), and intradialytic hypotension (<a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>). </p> </section> <section id="CD011064-sec-0046"> <h5 class="title">Dihydropyridine CCB versus non‐dihydropyridine CCB</h5> <p><a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> (40 participants) compared dihydropyridine CCB (amlodipine) to a non‐dihydropyridine CCB (verapamil). </p> <p>The outcomes assessed were predialysis systolic and diastolic blood pressure, cardiovascular death, and other side effects (including headache). </p> </section> <section id="CD011064-sec-0047"> <h5 class="title">Dihydropyridine CCB versus other antihypertensives</h5> <p>Eight studies (1037 participants) compared a dihydropyridine CCB to ACEi (including enalapril, trandolapril, perindopril and ramipril) (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>) or an ARB (telmisartan or losartan) (<a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>). </p> <p>Outcomes reported were changes in changes in predialysis systolic and diastolic blood pressure (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>), cardiovascular death (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>), and intradialytic hypotension (<a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>) </p> <p><a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a> (47 participants) compared lercanidipine to ARB (telmisartan) and <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a> (39 participants) compared amlodipine to both enalapril and losartan, however no outcome data were extractable. </p> </section> </section> <section id="CD011064-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded 16 studies (20 reports); 15 studies did not have the required follow‐up period (<a href="./references#CD011064-bbs2-0014" title="AslamS , SanthaT , LeoneA , WilcoxC . Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney International2006;70(12):2109-15. [MEDLINE: 17063175]SanthaT , AslamS , GoninJ , LlachF , UmansJ , WilcoxCS . The effects of valsartan and amlodipine therapy on oxidative stress and L-arginine metabolism in patients on maintenance hemodialysis: a randomized double-blind crossover study [abstract no: SA-FC092]. Journal of the American Society of Nephrology2005;16:102A. ">Aslam 2006</a>; <a href="./references#CD011064-bbs2-0015" title="AtabakS , TazikiO , ArganiH , AbolghasemiR , ZangnehHF , RahmaniL . Effects of oral enalapril and verapamil on dialysis adequacy and solute clearance in chronic ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases &amp; Transplantation2013;24(6):1170-74. [MEDLINE: 24231479]">Atabak 2013</a>; <a href="./references#CD011064-bbs2-0016" title="CiceG , Di BenedettoA , TagliamonteE , FerraraL , SoriceP , IaconoA . Effectiveness and tolerability of bisoprolol vs. nifedipine in uremic patients with ischemic cardiopathy in dialysis treatment [Efficacia e tollerabilita di bisoprololo e nifedipina in pazienti uremici con cardiopatia ischemica in trattamento dialitico]. Cardiologia1997;42(4):397-403. [MEDLINE: 9244644]">Cice 1997</a>; <a href="./references#CD011064-bbs2-0017" title="CiceG , FerraraL , TagliamonteE , Di BenedettoA , IaconoA . Incremental doses of diltiazem in patients with coronary artery disease in end-stage renal failure maintained on hemodialysis: which is the optimal dose? [Diltiazem a dosaggi crescenti in pazienti uremici emodializzati con cardiopatia ischemica: qual e il dosaggio ottimale?]. Cardiologia1998;43(12):1337-43. [MEDLINE: 9988942]">Cice 1998</a>; <a href="./references#CD011064-bbs2-0018" title="CiceG , Di BenedettoA , D'AndreaA , D'IsaS , FerraraL , RussoPE , et al. Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease: a double-blind, randomized, crossover, placebo-controlled trial. Journal of the American Society of Nephrology2003;14(4):1006-11. [MEDLINE: 12660335]">Cice 2003</a>; <a href="./references#CD011064-bbs2-0019" title="IqbalMM , NaharN , ChowdhuryAA , AhmedS , AlamKS , KhanMF , et al. Efficacy of enalapril and sustained-release nifedipine in controlling blood pressure of patients on maintenance hemodialysis: observations from ongoing EDIT trial [abstract]. Hemodialysis International2011;15(1):141-2. [EMBASE: 70587180]">EDIT 2011</a>; <a href="./references#CD011064-bbs2-0020" title="KojimaM , TaniguchiM , SatoK , UedaR , DohiY . Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days--a randomized crossover trial between benidipine and nifedipine. Nephron2004;97(2):c49-53. [MEDLINE: 15218330]">Kojima 2004</a>; <a href="./references#CD011064-bbs2-0021" title="NakanoN , IshimitsuT , TakahashiT , InadaH , OkamuraA , OhbaS , et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. International Heart Journal2010;51(3):188-92. [MEDLINE: 20558909]">Nakano 2010</a>; <a href="./references#CD011064-bbs2-0023" title="Rojas-CamposE , Cortes-SanabriaL , Martinez-RamirezHR , GonzalezL , Martin-del-CampoF , Gonzalez-OrtizM , et al. Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International2005;25(6):576-82. [MEDLINE: 16411525]Rojas-CamposE , Martinez-RamirezH , Cortes-SanabriaL , CamachoR , Martin-del-CampoF , Cueto-ManzanoAM . Oral verapamil increases ultrafiltration and peritoneal small solute clearance of CAPD patients [abstract no: SA-FC130]. Journal of the American Society of Nephrology2005;16:110A. [CENTRAL: CN-00583927] Rojas-CamposE , Martinez-RamirezH , Cortes-SanabriaL , Zavala-SanchezA , Camacho-MiramontesR , delCampoFM , et al. Oral verapamil increases ultrafiltration and peritoneal small solute clearance of continuous ambulatory peritoneal dialysis (CAPD) patients [abstract no: MP448]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v349. ">Rojas‐Campos 2005</a>; <a href="./references#CD011064-bbs2-0024" title="SalvettiA , BozzoMV , GraziolaM , Abdel-HaqB . Acute hemodynamic effect of nifedipine in hypertensives with chronic renal failure: the influence of volume status. Journal of Cardiovascular Pharmacology1987;10 Suppl 10:S143-6. [MEDLINE: 2455118]">Salvetti 1987</a>; <a href="./references#CD011064-bbs2-0025" title="SchifflH , StrasserT . Hemodialysis-related leukotriene B4 generation and neutropenia during calcium channel blockade. Biomaterials, Artificial Cells, &amp; Immobilization Biotechnology1991;19(1):85-96. [MEDLINE: 1721550]">Schiffl 1991</a>; <a href="./references#CD011064-bbs2-0026" title="ShermanRA , CasaleP , CodyR , HortonM . Effect of pre-dialysis verapamil (V) on blood pressure (BP) during hemodialysis (HD) [abstract]. Kidney International1990;37(1):319. ShermanRA , CasaleP , CodyR , HortonMW . Effect of predialysis verapamil on intradialytic blood pressure in chronic hemodialysis patients. American Society for Artificial Internal organs1990;36(2):67-9. [MEDLINE: 2340210]">Sherman 1990</a>; <a href="./references#CD011064-bbs2-0027" title="SinghatonS , SupapornT , KarnchanakoonI , SupasindhuO , ChoowichianP , LuwiraU . Differential blood pressure between daily morning versus evening dose of amlodipine assessed by ambulatory blood pressure monitoring [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):491A. ">Singhaton 2001</a>; <a href="./references#CD011064-bbs2-0028" title="SoniJK , BrierME , OusephR , AronoffGR . Supervised antihypertensive pharmacotherapy in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2000;11(Sept):355A. ">Soni 2000</a>; <a href="./references#CD011064-bbs2-0029" title="ZuccalaA , SantoroA , FerrariG , ZucchelliP . Pathogenesis of hypertension in hemodialysis patients: a pharmacological study. Kidney International - Supplement1988;34(25):S190-1. [MEDLINE: 3054237]">Zuccala 1988</a>) and one study used an inappropriate intervention (<a href="./references#CD011064-bbs2-0022" title="CharytanD . A phase IV randomized, double-blind, active-controlled, single-center study of the safety and effects on cardiac structure and function of hydralazine and isosorbide dinitrate in patients with hemodialysis dependent ESRD. www.clinicaltrials.gov/ct2/show/NCT02228408 (first received 26 August 2014). ">NCT02228408</a>). See <a href="./references#CD011064-sec-0085" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD011064-sec-0049"> <h4 class="title">Studies awaiting classification</h4> <p><a href="./references#CD011064-bbs2-0030" title="CiceG . Cardiovascular events in hypertensive hemodialysed patients: aliskiren versus amlodipine. a randomized, double-blind study. www.clinicaltrials.gov/ct2/show/NCT01394770 (first received 13 July 2011). ">NCT01394770</a> was registered in 2009 but never published; it was registered more than 10 years ago however its current recruitment status is listed as unknown; therefore, we have assessed it as awaiting classification. </p> </section> <section id="CD011064-sec-0050"> <h4 class="title">Ongoing studies</h4> <p>Our search did not identify any ongoing studies.</p> </section> </section> <section id="CD011064-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, the risk of bias in the included studies are reported in <a href="#CD011064-fig-0002">Figure 2</a>, whilst the risk of bias in each study is shown in <a href="#CD011064-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011064-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011064-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011064-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011064-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011064-sec-0052"> <h4 class="title">Allocation</h4> <section id="CD011064-sec-0053"> <h5 class="title">Random sequence generation</h5> <p>Eight studies were judged to be at low risk of selection bias since they reported an appropriate random sequence generation procedure (<a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). The remaining five studies were judged to be at unclear risk of bias (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>). </p> </section> <section id="CD011064-sec-0054"> <h5 class="title">Allocation concealment</h5> <p><a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a> was judged to be at a low risk of bias related to allocation concealment, while the remaining 12 studies were judged to be at unclear risk of bias (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). </p> </section> </section> <section id="CD011064-sec-0055"> <h4 class="title">Blinding</h4> <section id="CD011064-sec-0056"> <h5 class="title">Performance bias</h5> <p>Two studies (<a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>) were blinded and judged to be at low risk of bias. Eight studies were not blinded and were at high risk of performance bias (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>), while the risk of bias in three studies (<a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>) was judged to be uncertain. </p> </section> <section id="CD011064-sec-0057"> <h5 class="title">Detection bias</h5> <p>Ten studies were judged to be at low risk of bias due to blinding of outcome assessors (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>). There studies were adjudicated to be at high risk of detection bias (<a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). </p> </section> </section> <section id="CD011064-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>) were judged to be at low risk of attrition bias. Seven studies were considered at high risk due to incomplete outcome data (<a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). The remaining three studies were considered to be at unclear risk of bias (<a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>). </p> </section> <section id="CD011064-sec-0059"> <h4 class="title">Selective reporting</h4> <p>Eight studies published data on all expected outcomes and were considered to be at low risk of reporting bias (<a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). Five studies (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>) were only available as abstracts and were considered to be at high risk of bias. In addition, <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a> failed to report some outcomes related to the control group. </p> </section> <section id="CD011064-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Five studies were judged to be at low risk from other potential sources of bias (<a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>; <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). Eight studies were assessed to be at high risk of other potential sources of bias. Three studies (<a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>, <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>) were funded by pharmaceutical companies or authors had conflict of interests, and this may have introduced some bias. Other potential sources of bias included abstract‐only publications in five studies (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>). </p> </section> </section> <section id="CD011064-sec-0061"> <h3 class="title" id="CD011064-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD011064-tbl-0001"><b>Summary of findings 1</b> Dihydropyridine calcium channel blockers versus placebo/control in people with chronic kidney disease requiring dialysis</a>; <a href="./full#CD011064-tbl-0002"><b>Summary of findings 2</b> Dihydropyridine calcium channel blockers versus other antihypertensives in people with chronic kidney disease requiring dialysis</a>; <a href="./full#CD011064-tbl-0003"><b>Summary of findings 3</b> Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with chronic kidney disease requiring dialysis</a> </p> <section id="CD011064-sec-0062"> <h4 class="title">Calcium channel blockers versus placebo/control/no treatment</h4> <p>Five studies (<a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>; <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>), randomising 451 adults undergoing haemodialysis, compared dihydropyridine CCBs to placebo or no treatment. The certainty of the evidence was low for all outcomes (<a href="./full#CD011064-tbl-0001">summary of findings Table 1</a>). </p> <p>Dihydropyridine CCBs may decrease predialysis systolic blood pressure level compared to placebo (<a href="./references#CD011064-fig-0004" title="">Analysis 1.1</a> (1 study, 39 participants): MD ‐27.00 mmHg, 95% CI ‐43.33 to ‐10.67; <i>low certainty evidence</i>) and diastolic blood pressure level (<a href="./references#CD011064-fig-0005" title="">Analysis 1.2</a> (2 studies, 76 participants): MD ‐13.56 mmHg, 95% CI ‐19.65 to ‐7.48; I<sup>2</sup> = 0%; <i>low certainty evidence</i>) compared to placebo or no treatment. </p> <p>The effect of dihydropyridine CCBs compared to placebo or no treatment on cardiovascular death was not estimable, since no events were reported in any of the studies (<a href="./references#CD011064-fig-0006" title="">Analysis 1.3</a>: 3 studies, 124 participants). </p> <p>Dihydropyridine CCBs may make little or no difference to intradialytic hypotension (<a href="./references#CD011064-fig-0007" title="">Analysis 1.4</a>: 2 studies, 287 participants): RR 0.54, 95% CI 0.25 to 1.15; I<sup>2</sup> = 0%;<i>low certainty evidence</i>) compared to placebo or no treatment. </p> <p>Other side effects and costs were not reported by any of the included studies.</p> <p>No studies compared non‐dihydropyridine CCBs to placebo or control.</p> </section> <section id="CD011064-sec-0063"> <h4 class="title">Calcium channel blockers versus other antihypertensives</h4> <p>Eight studies (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>) randomising 1037 adults treated with haemodialysis compared dihydropyridine CCBs to other antihypertensives. Five studies (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>) were abstract‐only publications. Four studies (<a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>), while meeting our inclusion criteria, had insufficient information and were not included in the meta‐analyses. The certainty of the evidence was low to very low (<a href="./full#CD011064-tbl-0002">summary of findings Table 2</a>). </p> <p>Dihydropyridine CCBs may make little or no difference to predialysis systolic (<a href="./references#CD011064-fig-0008" title="">Analysis 2.1</a> (4 studies, 180 participants): MD 2.44 mmHg, 95% CI ‐3.74 to 8.62; I<sup>2</sup> = 0%, <i>low certainty evidence</i>) and diastolic blood pressure (<a href="./references#CD011064-fig-0009" title="">Analysis 2.2</a> (4 studies, 180 participants): MD 1.49 mmHg, 95% CI ‐2.23 to 5.21; I<sup>2</sup> = 0%, <i>low certainty evidence</i>) compared to other antihypertensives. </p> <p>The effect of dihydropyridine CCBs compared to other antihypertensives on cardiovascular death was not estimable, since no events were reported in any of the studies (<a href="./references#CD011064-fig-0010" title="">Analysis 2.3</a>: 3 studies, 164 participants). </p> <p><a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a> reported one case of intradialytic hypotension in the dihydropyridine CCB group (<a href="./references#CD011064-fig-0011" title="">Analysis 2.4</a> (1 study, 92 participants): RR 2.88, 95% CI 0.12 to 68.79; <i>very low certainty evidence</i>). </p> <p>Other side effects and costs were not reported by any of the included studies.</p> <p>No studies compared non‐dihydropyridine CCBs to other antihypertensives.</p> </section> <section id="CD011064-sec-0064"> <h4 class="title">Dihydropyridine versus non‐dihydropyridine calcium channel blockers</h4> <p><a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> compared dihydropyridine CCB to non‐dihydropyridine CCB in 40 haemodialysis patients. The certainty of the evidence was low to very low (<a href="./full#CD011064-tbl-0003">summary of findings Table 3</a>). </p> <p><a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> reported may make little or no difference to predialysis systolic (<a href="./references#CD011064-fig-0012" title="">Analysis 3.1</a> (1 study, 40 participants): MD ‐4.00 mmHg, 95% CI ‐11.99 to 3.99; <i>low certainty evidence</i>) and diastolic blood pressure level (<a href="./references#CD011064-fig-0013" title="">Analysis 3.2</a> (1 study, 40 participants): MD ‐3.00 mmHg, 95% CI ‐7.06 to 1.06; <i>low certainty evidence</i>) between dihydropyridine and non‐dihydropyridine CCB. </p> <p>The effect of dihydropyridine CCB compared to non‐dihydropyridine CCB on cardiovascular death was not estimable, since no events were reported in either group (<a href="./references#CD011064-fig-0014" title="">Analysis 3.3</a>: 1 study, 40 participants). </p> <p>There was no evidence of a difference in other side effects (<a href="./references#CD011064-fig-0015" title="">Analysis 3.4</a> (1 study, 40 participants): RR 0.13, 95% CI 0.01 to 2.36; <i>very low certainty evidence</i>) between dihydropyridine CCB and non‐dihydropyridine CCB. Other side effects included headache. </p> <p><a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> did not report intradialytic hypotension or costs. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011064-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011064-sec-0065"></div> <section id="CD011064-sec-0066"> <h3 class="title" id="CD011064-sec-0066">Summary of main results</h3> <p>We found 13 studies that met our inclusion criteria (1459 randomised adults); five of these were available only as abstracts. Four of these studies (<a href="./references#CD011064-bbs2-0002" title="DasB , MishraTK , RoutraySN , BeheraM . Left ventricular mass regression in patients with end-stage renal disease [abstract no: 71]. Indian Heart Journal2003;55(5). [CENTRAL: CN-00716126] ">Das 2003</a>; <a href="./references#CD011064-bbs2-0003" title="NakaoN , TakeshiU , AtsushiT , TakadaM , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: W515]. Nephrology Dialysis Transplantation2003;18(Suppl 4):711. NakaoN , UsamiT , FukudaM , YoshidaA , KimuraG . Effects of blood pressure lowering and antihypertensive drug class on cardiovascular events of hemodialysis patients: results from HEmodialysis Angiotensin-inhibition Rescue Trial (HEART) [abstract no: SA-FC183]. Journal of the American Society of Nephrology2003;14(Nov):40A. [CENTRAL: CN-00446901] ">HEART 2003</a>; <a href="./references#CD011064-bbs2-0009" title="NakaoN , OhsakiS , TakadaM , TakahashiT , KayanoT . Trandolapril compared with slow-releasing nifedipine not only reduced mortality but also improved QOL of hypertensive hemodialysis patients [abstract no: A1854]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):368A. ">Nakao 1999</a>; <a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a>), while meeting our inclusion criteria, had insufficient information and were not included in the meta‐analyses. All studies were performed in haemodialysis patients. </p> <p>Random sequence generation and allocation concealment were at low risk of bias in eight and one studies, respectively. Two studies reported low risk methods for blinding of participants and investigators, and outcome assessment was blinded in 10 studies. Three studies were at low risk of attrition bias, eight studies were at low risk of selective reporting bias, and five studies were at low risk of other potential sources of bias. </p> <p>Dihydropyridine CCBs may decrease predialysis systolic and diastolic blood pressure when compared to placebo or no treatment, may make little or no difference to occurrence of intradialytic hypotension, whilst the effects on cardiovascular death was uncertain. </p> <p>Eight studies compared dihydropyridine CCBs with other antihypertensives. Dihydropyridine CCBs may make little or no difference to predialysis systolic and diastolic blood pressure, while the effects on cardiovascular death and occurrence of intradialytic hypotension compared to other antihypertensives were uncertain. </p> <p>Dihydropyridine CCBs may make little or no difference to predialysis systolic and diastolic blood pressure, while the effects on cardiovascular death and other side effects compared to non‐dihydropyridine CCBs were uncertain. </p> </section> <section id="CD011064-sec-0067"> <h3 class="title" id="CD011064-sec-0067">Overall completeness and applicability of evidence</h3> <p>This review searched for evidence supporting the use of CCBs in patients with CKD requiring dialysis. There were inadequate numbers of well conducted RCTs to answer our question conclusively. </p> <p>Overall, data for carrying out the comparison between dihydropyridine CCBs and other antihypertensives came from four studies with 180 adult patients on maintenance haemodialysis (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). Side effects were rarely reported (<a href="#CD011064-tbl-0004">Table 1</a>) and no studies addressed total healthcare cost. Studies done in children and in patients undergoing peritoneal dialysis were not found after an extensive literature search. </p> <div class="table" id="CD011064-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies reporting adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events in the intervention group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events in the control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrendipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; no deaths were reported; no postdialysis hypotension was reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 20 participants, the following adverse events were reported: dropped out due to DBP persistently &gt; 114 mmHg (1). No death was reported. No postdialysis hypotension was reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrendipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perindopril</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 14 participants, the following adverse events were reported: withdrawn due to DBP &gt; 95 mmHg (4). No deaths were reported. No serious adverse event was reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 16 participants, the following adverse events were reported: withdrawn due to DBP &gt; 95 mmHg (2). No deaths were reported. No serious adverse events were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cilnidipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 25 participants, the following adverse events were reported: cardiogenic shock (due to acute coronary syndrome) (1), needed to decrease the dry weight more that 1% due to remarkable volume overload (3). No deaths were reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 11 participants, the following adverse events were reported: colon cancer (1), hypotension (1), hypertension (1), needed to decrease the dry weight more that 1% due to remarkable volume overload (1). No deaths were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nifedipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; no deaths were reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 20 participants, the following adverse events were reported: dropped out due to DBP persistently &gt; 114 mmHg (1). No deaths were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Losartan or enalapril</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall, of 61 participants there were: acute MI (3), myocarditis (2), death from pulmonary bleeding (1). However, no data were reported per group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall, of 61 participants there were: acute MI (3), myocarditis (2), death from pulmonary bleeding (1). However, no data were reported per group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 123 participants, the following adverse events were reported: 15 deaths.</p> <p>Overall, 26 sudden deaths, 7 infections, 4 cancers were recorded but data were not reported per group. </p> <p>The flow chart showed that the drug was discontinued because of adverse events in 8 participants. 18 participants reported a cardiovascular event, including MI, need for coronary angioplasty or coronary bypass surgery, Ischaemic stroke, and peripheral vascular disease with the need for amputation or angioplasty </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 128 participants, the following adverse events were reported: 22 deaths.</p> <p>Overall, 26 sudden deaths, 7 infections, 4 cancers were recorded but data were not reported per group. </p> <p>The flow chart showed that the drug was discontinued because of adverse events in 12 participants; 33 participants reported a cardiovascular event, including MI, need for coronary angioplasty or coronary bypass surgery, Ischaemic stroke, and peripheral vascular disease with the need for amputation or angioplasty </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 21 participants, the following adverse events were reported: lower limb oedema (2), cough (2), cutaneous rash (1). No deaths were reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 19 participants, the following adverse events were reported: lower limb oedema (7), headache (3). No deaths were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramipril</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 47 participants, the following adverse events were reported: death (1), hypotension (1), drug intolerance (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 45 participants, the following adverse events were reported: 1 cough (1), hyperkalaemia (1) lead to the discontinuation from the study </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DBP ‐ diastolic blood pressure; MI ‐ myocardial infarction</p> </div> </div> <p>No studies compared the effect of different dihydropyridine CCBs, different non‐dihydropyridine CCBs, or different doses of the same drug. No studies compared non‐dihydropyridines CCBs to other antihypertensives, placebo or control. </p> <p>The majority of studies included in the meta‐analyses were performed in Europe; France (<a href="./references#CD011064-bbs2-0001" title="AlbitarS , GeninR , Fen-ChongM , ScholhnD , ServeauxMO , ChuetC . Impact of ACE inhibitors on erythropoiesis in haemodialysis (HD) populations [abstract]. Nephrology Dialysis Transplantation1997;12(9):A190. [CENTRAL: CN-00261441] AlbitarS , GeninR , Fen-ChongM , ServeauxMO , ChuetC . Enalapril versus nifedipine in patients on maintenance haemodialysis (HD) with erythropoietin-induced hypertension (HT) [abstract]. Nephrology1997;3(Suppl 1):S515. ">Albitar 1997</a>; <a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a>; <a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a>; <a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a>), Germany (<a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a>), Italy (<a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a>), Russia (<a href="./references#CD011064-bbs2-0004" title="KozlovaT , ErmolenkoV , ShutovE . Effects of perindopril, amlodipine and combination of perindopril and amlodipine on left ventricular mass and diastolic function in non-diabetic haemodialysis patients with hypertension [abstract no: MP408]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv436. ">Kozlova 2006</a>), and Turkey (<a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a>). <a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a> was performed in Japan. This clearly affects the external validity of these findings, as these findings cannot be applied wholesome since clinical practice differs based on region. </p> <p>The standardisation of outcomes reporting in future studies might enhance better evidence in dialysis setting. The Standardised Outcomes in Nephrology (SONG) initiative suggest that fatigue, cardiovascular disease, vascular access, and death (<a href="./references#CD011064-bbs2-0051" title="SONG Initiative. Standardised outcomes in nephrology. www.songinitiative.org/projects/song-hd/ (accessed 21 August 2020).">SONG‐HD</a>) are the core outcomes set to report in all studies in haemodialysis setting, while infection, cardiovascular disease, death, technique survival and life participation are the compulsory outcomes to assess in studies on peritoneal dialysis (<a href="./references#CD011064-bbs2-0052" title="SONG Initiative. Standardised outcomes in nephrology. www.songinitiative.org/projects/song-pd/ (accessed 21 August 2020).">SONG‐PD</a>). </p> </section> <section id="CD011064-sec-0068"> <h3 class="title" id="CD011064-sec-0068">Quality of the evidence</h3> <p>The quality of the evidence was assessed according to the recommendations of the GRADE Working Group (<a href="./references#CD011064-bbs2-0039" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Overall, the quality of evidence was generally either low or very low. </p> <p>Twelve studies did not report allocation concealment and most studies reported inadequate blinding of investigators and participants, attrition, and other sources of bias, reducing the certainty of treatment benefits and harms. Only <a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a> was considered at low risk of bias for all domains. As many outcomes, such as predialysis systolic and diastolic blood pressure and intradialytic hypotension, were measured using objective measures, 10 studies were at low risk of bias for outcome assessment. Heterogeneity was low across the studies included in the meta‐analysis. </p> </section> <section id="CD011064-sec-0069"> <h3 class="title" id="CD011064-sec-0069">Potential biases in the review process</h3> <p>Although we applied standard Cochrane methodology, residual bias in the review process was inevitably present. It is possible that relevant but unpublished data (those studies with neutral or negative effects) may have been missed. Analysis for evidence of such publication bias was not possible due to the small number of included studies. </p> <p>Four studies did not report key outcomes in a format available for meta‐analysis. The included studies did not report total healthcare costs and no events were reported for cardiovascular death. </p> <p>Only <a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> investigated the effect of dihydropyridine versus non‐dihydropyridine CCBs. Furthermore, we found no studies that involved children or people undergoing peritoneal dialysis; and 12 studies were conducted in Europe and this may limit the generalisability of our findings. </p> </section> <section id="CD011064-sec-0070"> <h3 class="title" id="CD011064-sec-0070">Agreements and disagreements with other studies or reviews</h3> <p>We found one systematic review and meta‐analysis that investigated the effects of CCBs compared to ACEi or ARB in people with CKD stages 3‐5 including dialysis (<a href="./references#CD011064-bbs2-0043" title="LinYC , LinJW , WuMS , ChenKC , PengCC , KangYN . Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. Plos One2017;12(12):e0188975. [MEDLINE: 29240784]">Lin 2017</a>). Our Cochrane review is consistent with the findings showed in that review<b>,</b> reporting no significant differences in change in blood pressure and death between the two groups. However, differences between <a href="./references#CD011064-bbs2-0043" title="LinYC , LinJW , WuMS , ChenKC , PengCC , KangYN . Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. Plos One2017;12(12):e0188975. [MEDLINE: 29240784]">Lin 2017</a> and our updated review were related to the inclusion of patients in CKD stages 3 to 5: although the author included 21 studies, only four studies were performed in ESKD. In addition, <a href="./references#CD011064-bbs2-0043" title="LinYC , LinJW , WuMS , ChenKC , PengCC , KangYN . Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. Plos One2017;12(12):e0188975. [MEDLINE: 29240784]">Lin 2017</a> excluded studies that compared dihydropyridine CCBs to placebo, no treatment or non‐dihydropyridine CCBs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011064-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011064-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011064-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011064-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 1: Predialysis systolic blood pressure" data-id="CD011064-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 1: Predialysis systolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 2: Predialysis diastolic blood pressure" data-id="CD011064-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 2: Predialysis diastolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 3: Cardiovascular death" data-id="CD011064-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 3: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 4: Intradialytic hypotension" data-id="CD011064-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Dihydropyridine calcium channel blocker versus placebo/control/usual treatment, Outcome 4: Intradialytic hypotension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 1: Predialysis systolic blood pressure" data-id="CD011064-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 1: Predialysis systolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 2: Predialysis diastolic blood pressure" data-id="CD011064-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 2: Predialysis diastolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 3: Cardiovascular death" data-id="CD011064-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 3: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 4: Intradialytic hypotension" data-id="CD011064-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Dihydropyridine calcium channel blockers versus other antihypertensives, Outcome 4: Intradialytic hypotension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 1: Predialysis systolic blood pressure" data-id="CD011064-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 1: Predialysis systolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 2: Predialysis diastolic blood pressure" data-id="CD011064-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 2: Predialysis diastolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 3: Cardiovascular death" data-id="CD011064-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 3: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011064-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/urn:x-wiley:14651858:media:CD011064:CD011064-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 4: Other side effects" data-id="CD011064-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_t/tCD011064-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Dihydropyridine versus non‐dihydropyridine calcium channel blocker, Outcome 4: Other side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/media/CDSR/CD011064/image_n/nCD011064-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011064-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus placebo/control in people with chronic kidney disease requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydropyridine calcium channel blockers versus placebo/control in people with CKD requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD requiring dialysis<br/><b>Setting:</b> France, Germany, Japan, Russia </p> <p><b>Intervention:</b> dihydropyridine calcium channel blockers (amlodipine, cilnidipine or nitrendipine)<br/><b>Comparison:</b> placebo/control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dihydropyridine calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis systolic blood pressure</b><br/>follow‐up 3.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis systolic blood pressure level in the dihydropyridine calcium channel blockers group was 27.00 mmHg lower (43.33 to 10.67 mmHg lower) than the placebo group <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis diastolic blood pressure</b><br/>mean follow‐up 4.9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis diastolic blood pressure level in the placebo/control group ranged from 98 to 104.1 mmHg </p> <p>The mean predialysis diastolic blood pressure level in the placebo/control group was 13.56 mmHg lower (19.65 to 7.48 mmHg lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>mean follow‐up 3.4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradialytic hypotension</b> </p> <p>mean follow‐up 16.4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/>(31 to 141) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54 (0.25 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>3,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> Chronic kidney disease; <b>HD:</b> Haemodialysis; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Studies were not designed to measure effects of dihydropyridine calcium channel blockers on predialysis systolic blood pressure level in haemodialysis<br/><sup>2</sup> Evidence certainty was downgraded by one level due to study limitations. The study had unclear risks for allocation concealment and blinding (participants and/or investigators)<br/><sup>3</sup> Evidence certainty was downgraded by one level due to the small number of participants/events (optimal Information size criterion not met)<br/><sup>4</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risk for sequence generation, all studies had unclear risks for allocation concealment and some of them were not blinded (participants and/or investigators)<br/><sup>5</sup> Cardiovascular death was reported by as a single study with zero events in both groups; studies were not designed to measure effects of dihydropyridine calcium channel blockers or placebo/control on cardiovascular death in HD<br/><sup>6</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risks for allocation concealment and were not blinded (participants and/or investigators) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus placebo/control in people with chronic kidney disease requiring dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011064-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus other antihypertensives in people with chronic kidney disease requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydropyridine calcium channel blockers versus other antihypertensives in people with CKD requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD requiring dialysis<br/><b>Setting:</b> France, Turkey, Russia </p> <p><b>Intervention:</b> dihydropyridine calcium channel blockers (amlodipine or nifedipine)<br/><b>Comparison:</b> other antihypertensives (all studies reported ACEi including, enalapril, perindopril or ramipril) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other antihypertensives</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dihydropyridine calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis systolic blood pressure</b><br/>mean follow‐up 10.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis systolic blood pressure level in the other antihypertensive group ranged from 129 to 150 mmHg </p> <p>The mean predialysis systolic blood pressure level in the dihydropyridine calcium channel blockers group was 2.44 mmHg higher (3.74 lower to 8.62 mmHg higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis diastolic blood pressure</b><br/>mean follow‐up 10.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis diastolic blood pressure level in the other antihypertensive group ranged from 80 to 88.3 mmHg </p> <p>The mean predialysis diastolic blood pressure level in the dihydropyridine calcium channel blockers group was 1.49 mmHg higher (2.23 lower to 5.21 mmHg higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>mean follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradialytic hypotension</b> </p> <p>follow‐up 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1/47**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.88</p> <p>(0.12 to 68.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>5,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other side effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> Chronic kidney disease; <b>HD:</b> Haemodialysis; <b>ACEi:</b> Angiotensin‐converting enzyme inhibitors; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> <p>**Event rate derived from the raw data. A "per thousand" rate is non‐informative in view of the scarcity of evidence and zero events in the control group. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risk for sequence generation, all studies had unclear risks for allocation concealment and the majority of them were not blinded (participants and/or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to the small number of participants/events (optimal information size criterion not met) </p> <p><sup>3</sup> Cardiovascular death was reported by as a single study with zero events in both groups; studies were not designed to measure cardiovascular death<br/><sup>4</sup> Occurrence of intradialytic hypotension was reported by as a single study; studies were not designed to measure the occurrence of intradialytic hypotension in HD </p> <p><sup>5</sup> Evidence certainty was downgraded by one level due to study limitations. The study had unclear risks for allocation concealment and was not blinded (participants and/or investigators) </p> <p><sup>6</sup> Evidence certainty was downgraded by two levels due to imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus other antihypertensives in people with chronic kidney disease requiring dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011064-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with chronic kidney disease requiring dialysis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with CKD requiring dialysis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD requiring dialysis </p> <p><b>Setting:</b> Italy </p> <p><b>Intervention:</b> dihydropyridine calcium channel blockers (amlodipine) </p> <p><b>Comparison:</b> non‐dihydropyridine calcium channel blockers (verapamil) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Non‐dihydropyridine calcium channel blockers</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dihydropyridine calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis systolic blood pressure</b> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis systolic blood pressure level in the dihydropyridine calcium channel blockers group was 4 mmHg lower (11.99 lower to 3.99 mmHg higher) than non‐dihydropyridine calcium channel blockers <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Predialysis diastolic blood pressure</b> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean predialysis diastolic blood pressure level in the dihydropyridine calcium channel blockers group was 3.00 mmHg lower (7.06 lower to 1.06 mmHg higher) than non‐dihydropyridine calcium channel blockers <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>1,3,4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradialytic hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other side effects</b><sup>1,5</sup> </p> <p>follow‐up 2.8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3/19 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.13</b> </p> <p>(0.01 to 2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> Chronic kidney disease; <b>HD:</b> Haemodialysis; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> <p>**Event rate derived from the raw data. A "per thousand" rate is non‐informative in view of the scarcity of evidence and zero events in the dihydropyridine calcium channel blocker group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Studies not designed to measure this outcome<br/><sup>2</sup> Evidence certainty was downgraded by one level due to study limitations. The study had unclear risks for allocation concealment and was not blinded (participants and/or investigators)<br/><sup>3</sup> Evidence certainty was downgraded by one level due to the small number of participants/events (optimal information size criterion not met) </p> <p><sup>4</sup> Cardiovascular death was reported by as a single study with zero events in both groups<br/><sup>5</sup> Other side effects included headache reported in non‐dihydropyridine calcium channel blockers group, while no events were reported in dihydropyridine calcium channel blockers group </p> <p><sup>6</sup> Evidence certainty was downgraded by two levels due to imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Dihydropyridine versus non‐dihydropyridine calcium channel blockers in people with chronic kidney disease requiring dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011064-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies reporting adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events in the intervention group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events in the control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0005" title="LondonGM , MarchaisSJ , GuerinAP , MetivierF , SafarME , FabianiF , et al. Salt and water retention and calcium blockade in uremia. Circulation1990;82(1):105-13. [MEDLINE: 2364508]">London 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrendipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; no deaths were reported; no postdialysis hypotension was reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 20 participants, the following adverse events were reported: dropped out due to DBP persistently &gt; 114 mmHg (1). No death was reported. No postdialysis hypotension was reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0006" title="LondonGM , PannierB , GuerinAP , MarchaisSJ , SafarME , CucheJL . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation1994;90(6):2786-96. [MEDLINE: 7994822]">London 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrendipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perindopril</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 14 participants, the following adverse events were reported: withdrawn due to DBP &gt; 95 mmHg (4). No deaths were reported. No serious adverse event was reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 16 participants, the following adverse events were reported: withdrawn due to DBP &gt; 95 mmHg (2). No deaths were reported. No serious adverse events were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0007" title="FujimotoN , ItoT , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. Effects of l/n-type calcium channel blocker cilnidipine on ambulatory blood pressure and blood pressure variability in patients with intradialytic hypertension [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii51-iii5. [EMBASE: 617290855]ItoT , FujimotoN , IshikawaE , DohiK , FujimotoM , MurataT , et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clinical &amp; Experimental Hypertension2019;41(1):92-9. [MEDLINE: 29584458]ItoT , FujimotoN , IshikawaE , DohiK , KiyoharaM , TakeuchiH , et al. The effect of cilnidipine on intradialytic blood pressure in intradialytic hypertensive patients: A multicenter, prospective, randomized, open-label study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii472. [EMBASE: 617291253]">LONDON 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cilnidipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 25 participants, the following adverse events were reported: cardiogenic shock (due to acute coronary syndrome) (1), needed to decrease the dry weight more that 1% due to remarkable volume overload (3). No deaths were reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 11 participants, the following adverse events were reported: colon cancer (1), hypotension (1), hypertension (1), needed to decrease the dry weight more that 1% due to remarkable volume overload (1). No deaths were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0008" title="MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 1:S74-8. [MEDLINE: 1723463]MarchaisSJ , BoussacI , GuerinAP , DelavauxG , MetivierF , LondonGM . Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. Journal of Cardiovascular Pharmacology1991;18 Suppl 5:S14-8. [MEDLINE: 1725796]">Marchais 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nifedipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; no deaths were reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 20 participants, the following adverse events were reported: dropped out due to DBP persistently &gt; 114 mmHg (1). No deaths were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0010" title="ShibasakiY , MasakiH , NishiueT , MatsubaraH , NishikawaM , IwasakaT . Angiotensin II type-1 receptor antagonist losartan has greater anti-fibrotic effect than ACE inhibitor in patients with end stage renal disease [abstract]. Nephrology Dialysis Transplantation2001;16(6):A128. [CENTRAL: CN-00447711] ShibasakiY , MasakiH , NishiueT , NishikawaM , MatsubaraH , IwasakaT . Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron2002;90(3):256-61. [MEDLINE: 11867945]ShibasakiY , MasakiH , NishiueT , NishikawaM , TakahashiH , MatsubaraH , et al. Angiotensin II receptor antagonist suppress left ventricular hypertrophy and fibrosis in patients with end stage renal disease [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):245A. [CENTRAL: CN-00447712] ShibasakiY , NishiueT , MasakiH , MatsubaraH , IwasakaT . Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho [Japanese Journal of Clinical Medicine]2002;60(10):1992-8. [MEDLINE: 12397697]ShibasakiY , NishiueT , MasakiH , TamuraK , MatsumotoN , MoriY , et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension Research - Clinical &amp; Experimental2005;28(10):787-95. [MEDLINE: 16471172]">Shibasaki 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Losartan or enalapril</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall, of 61 participants there were: acute MI (3), myocarditis (2), death from pulmonary bleeding (1). However, no data were reported per group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall, of 61 participants there were: acute MI (3), myocarditis (2), death from pulmonary bleeding (1). However, no data were reported per group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0011" title="TepelM , HopfenmuellerW , ScholzeA , MaierA , ZidekW . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3605-12. [MEDLINE: 18511605]">Tepel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 123 participants, the following adverse events were reported: 15 deaths.</p> <p>Overall, 26 sudden deaths, 7 infections, 4 cancers were recorded but data were not reported per group. </p> <p>The flow chart showed that the drug was discontinued because of adverse events in 8 participants. 18 participants reported a cardiovascular event, including MI, need for coronary angioplasty or coronary bypass surgery, Ischaemic stroke, and peripheral vascular disease with the need for amputation or angioplasty </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 128 participants, the following adverse events were reported: 22 deaths.</p> <p>Overall, 26 sudden deaths, 7 infections, 4 cancers were recorded but data were not reported per group. </p> <p>The flow chart showed that the drug was discontinued because of adverse events in 12 participants; 33 participants reported a cardiovascular event, including MI, need for coronary angioplasty or coronary bypass surgery, Ischaemic stroke, and peripheral vascular disease with the need for amputation or angioplasty </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0012" title="TimioM , VerduraC , LolliS , LupparelliA . A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clinical Drug Investigation1997;13(Suppl 1):73-6. [EMBASE: 27361661]">Timio 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Verapamil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 21 participants, the following adverse events were reported: lower limb oedema (2), cough (2), cutaneous rash (1). No deaths were reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 19 participants, the following adverse events were reported: lower limb oedema (7), headache (3). No deaths were reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011064-bbs2-0013" title="YilmazR , AltunB , AriciM , AkinciD , OzerN , ErdemY , et al. Effects of amlodipine and ramipril on cardiovascular system in hemodialysis patients [abstract no: PUB407]. Journal of the American Society of Nephrology2005;16:870A. YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [MEDLINE: 20722555]YilmazR , KahramanS , AltunB , GenctoyG , AkinciD , OzerN , et al. Effects of amlodipine and ramipril on left ventricular mass index and carotid atherosclerosis in hemodialysis patients [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:352. [CENTRAL: CN-00509571] ">Yilmaz 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramipril</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 47 participants, the following adverse events were reported: death (1), hypotension (1), drug intolerance (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Among 45 participants, the following adverse events were reported: 1 cough (1), hyperkalaemia (1) lead to the discontinuation from the study </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>DBP ‐ diastolic blood pressure; MI ‐ myocardial infarction</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies reporting adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/full#CD011064-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011064-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dihydropyridine calcium channel blocker versus placebo/control/usual treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Predialysis systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Predialysis diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.56 [‐19.65, ‐7.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Intradialytic hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.25, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dihydropyridine calcium channel blocker versus placebo/control/usual treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011064-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus other antihypertensives</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Predialysis systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [‐3.74, 8.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Predialysis diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [‐2.23, 5.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Intradialytic hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dihydropyridine calcium channel blockers versus other antihypertensives</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011064-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dihydropyridine versus non‐dihydropyridine calcium channel blocker</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Predialysis systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Predialysis diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Other side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dihydropyridine versus non‐dihydropyridine calcium channel blocker</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011064.pub2/references#CD011064-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011064.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011064-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011064-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011064-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011064-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011064-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011064-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011064-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011064-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011064\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011064\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011064\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011064\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011064\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011064.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011064.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011064.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011064.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011064.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725302575"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011064.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725302579"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011064.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e77e52a3c936e',t:'MTc0MDcyNTMwMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 